Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.91 USD
-1.09 (-4.54%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $22.92 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
NTLA 22.91 -1.09(-4.54%)
Will NTLA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NTLA
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Other News for NTLA
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
Intellia Therapeutics Welcomes New CFO, Announces Executive Transition
Intellia Therapeutics Announces CFO Transition
Intellia Therapeutics appoints CFO
Intellia Therapeutics CFO Glenn Goddard to step down, Edward Dulac to succeed